SELLAS Life Sciences reports wider Q1 loss as REGAL Phase 3 AML trial nears key data readout and SLS009 advances in early-line studies.
Importance Rank:
1
SELLAS Life Sciences reports wider Q1 loss as REGAL Phase 3 AML trial nears key data readout and SLS009 advances in early-line studies.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.